At a glance
- Originator Sumitomo Pharmaceuticals
- Class Antipsoriatics; Osteoporosis therapies; Vitamin D analogues
- Mechanism of Action Vitamin D3 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Psoriasis
Most Recent Events
- 22 Feb 2000 No-Development-Reported for Psoriasis in Japan (Unknown route)
- 17 Sep 1996 Preclinical development for Psoriasis in Japan (Unknown route)